Haemonetics Corporation - 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended January 1, 2005
Business Overview: Haemonetics designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of donor and patient blood. The company operates in two primary product families: Donor (Blood Bank, Red Cell, Plasma) and Patient (Surgical Blood Salvage). Approximately 66% of revenues are generated internationally, primarily in Europe and Japan.
Key Financial Metrics
| Metric (in thousands) | Q3 FY2005 | Q3 FY2004 | 9M FY2005 | 9M FY2004 |
|---|---|---|---|---|
| Net Revenues | $98,098 | $90,737 | $283,623 | $266,508 |
| Gross Profit | $51,781 | $43,390 | $144,430 | $124,833 |
| Gross Margin | 52.8% | 47.8% | 50.9% | 46.8% |
| Operating Income | $15,300 | $14,373 | $44,173 | $31,942 |
| Net Income | $11,007 | $9,314 | $29,701 | $19,792 |
| Diluted EPS | $0.42 | $0.38 | $1.15 | $0.81 |
| Cash & Equivalents | $160,276 | $118,117 | $160,276 | $118,117 |
| Working Capital | $233,511 | $185,606 | $233,511 | $185,606 |
| Total Debt (Current + Long-term) | $49,221 | $58,260 | $49,221 | $58,260 |
Note: Debt figures derived from Balance Sheet (Notes payable/current maturities + Long-term debt).
Material Changes vs. Prior Period
- Revenue Growth: Q3 revenues increased 8.1% year-over-year. Approximately 6.1% of this increase was attributable to favorable foreign exchange rates (weaker USD against Yen and Euro). Organic growth was driven by Blood Bank, Red Cell, and Surgical product lines, partially offset by a 9.4% decline in Plasma revenue due to market consolidation and the loss of the Alpha Therapeutic Corporation customer.
- Profitability: Gross margin expanded to 52.8% in Q3 (from 47.8% prior year) due to favorable FX, reduced depreciation on customer equipment, and the absence of a $1.2 million excess inventory provision recorded in the prior year. Operating income rose 6.4% in Q3, though excluding FX, it would have decreased 23.8% due to higher operating expenses.
- Expense Increases: R&D expenses surged 61.7% in Q3, primarily due to a $1.7 million impairment charge on an acquired intangible asset and increased spending on new product development. SG&A expenses increased 19.9% due to personnel costs, Sarbanes-Oxley compliance, and legal fees.
- Cash Flow: Net cash provided by operating activities for the nine months ended Jan 1, 2005, was $48.5 million, an increase of $1.3 million from the prior year. Investing activities used $16.6 million, driven by a $5.0 million investment in a private company's preferred stock and $4.0 million in patent acquisitions.
Guidance, Outlook, and Risks
- Outlook: Management expects the natural tax rate to approximate 35.0% for the remainder of fiscal 2005. The company believes current capital sources (cash, internal flows, bank borrowings) are sufficient for the next 12 months.
- Foreign Exchange Risk: Approximately 66% of sales are in foreign currencies (Yen, Euro). A strengthening USD adversely affects results. The company uses forward contracts to hedge anticipated cash flows for up to 12 months.
- Market Risks: The commercial plasma market faces consolidation and oversupply, negatively impacting Plasma product revenue. The company is also subject to regulatory uncertainties and competitive pricing pressures.
- Accounting Changes: The company notes the upcoming adoption of SFAS 123R (Share-Based Payments), which will require recognizing stock-based compensation as an expense, potentially impacting future earnings. The impact cannot be predicted but will be significant.
- Contingencies: The company is engaged in various legal actions but believes liability will not materially affect financial position. A $1.7 million impairment charge was recognized in Q3 related to a re-evaluation of technology deployment plans.
Investor Verification Checklist
- Plasma Segment Decline: Verify the extent of the 15.1% nine-month revenue decline in the Plasma segment and the long-term impact of the Alpha Therapeutic Corporation customer loss.
- Intangible Asset Impairment: Review the details of the $1.7 million impairment charge on acquired technology and assess the viability of the remaining R&D pipeline.
- Foreign Exchange Sensitivity: Monitor the USD strength relative to the Yen and Euro, as FX accounted for a significant portion (approx. 6%) of revenue growth and 12% of gross profit growth in Q3.
- Stock-Based Compensation: Evaluate the potential impact of the upcoming SFAS 123R adoption on future net income and EPS, as the company currently uses the disclosure-only method.
- Debt Reduction: Confirm the trajectory of debt reduction, as total debt decreased from $58.3 million to $49.2 million over the nine-month period.